Thermo Fisher Develops New COVID-19 Antibody Assay Targeting Transplant Community
|
By HospiMedica International staff writers Posted on 11 Aug 2020 |

Illustration
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has developed a new serological assay targeted towards transplant candidates and recipients that can detect antibodies directed against COVID-19 (SARS-CoV-2).
Thermo Fisher's transplant diagnostic business has developed the LABScreen COVID Plus Assay which will be provided under the company's One Lambda brand representing leading in vitro diagnostic products for the transplant community. The assay leverages the Luminex xMAP technology to detect multiple distinct antibodies and fragments, making it more specific than current assays and able to reduce false positives caused by infections with common coronavirus. In combination with HLA antibody detection, the LABScreen COVID Plus reagents can help provide a more complete picture of a patient's antibody profile.
"We're proud of the role we play in responding to the pandemic, and this is one of many examples that demonstrate our ability and our commitment to fight COVID-19," said Nicole Brockway, president of the transplant diagnostic business for Thermo Fisher. "Transplant patients have unique needs compared to other COVID-19 patients, and with the support of Luminex and our research partners, we're delivering an innovative solution that's tailored to meet those needs."
Related Links:
Thermo Fisher Scientific Inc.
Thermo Fisher's transplant diagnostic business has developed the LABScreen COVID Plus Assay which will be provided under the company's One Lambda brand representing leading in vitro diagnostic products for the transplant community. The assay leverages the Luminex xMAP technology to detect multiple distinct antibodies and fragments, making it more specific than current assays and able to reduce false positives caused by infections with common coronavirus. In combination with HLA antibody detection, the LABScreen COVID Plus reagents can help provide a more complete picture of a patient's antibody profile.
"We're proud of the role we play in responding to the pandemic, and this is one of many examples that demonstrate our ability and our commitment to fight COVID-19," said Nicole Brockway, president of the transplant diagnostic business for Thermo Fisher. "Transplant patients have unique needs compared to other COVID-19 patients, and with the support of Luminex and our research partners, we're delivering an innovative solution that's tailored to meet those needs."
Related Links:
Thermo Fisher Scientific Inc.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreCritical Care
view channel
Eye Imaging AI Identifies Elevated Cardiovascular Risk
Many adults at risk for atherosclerotic cardiovascular disease are not identified until they undergo formal primary care assessment. Delayed risk recognition can postpone initiation of statins and lifestyle... Read more
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read moreSurgical Techniques
view channel
Fiber-Form Bone Graft Expands Intraoperative Options for Spinal Fusion
Spinal and orthopedic fusion procedures often require bone graft materials that handle predictably and support bone formation. Surgeons face added complexity in difficult anatomy and challenging fusion environments.... Read more
Ultrasound‑Aided Catheter Treatment Cuts Early Collapse in Pulmonary Embolism
Acute pulmonary embolism can cause rapid hemodynamic deterioration and early death in hospitalized and emergency patients. Systemic thrombolysis can dissolve clots but is limited by a high risk of major... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
Voice-Driven AI System Enables Structured GI Procedure Documentation
Documentation during gastrointestinal (GI) procedures often competes with real-time clinical decision-making and imposes a significant cognitive burden on physicians. Manual data entry and post-procedure... Read more
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel








